Fewer than one in 10 individuals eligible to benefit from GLP-1 drugs like Wegovy have access to them, states the WHO as it publishes its inaugural guidance on the medications.
Given in excess of 1,000,000,000 people worldwide currently classified as obese, it is urging increased and just availability to GLP-1 medication.
Per forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken.
"The new guidelines affirms that excess weight is a long-term condition that can be managed with thorough and lifelong support," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are key hurdles to universal access to the injections that can help people shift considerable weight, notes the agency.
Skinny Jab Supply Crisis
Despite the present most favorable case, the manufacturing of such drugs might only reach approximately 100 million people – under 10% of the global need, according to the WHO.
The guideline urges nations and manufacturers to increase availability, by strategies including patent sharing.
A patent on the active ingredient – the main component of Novo Nordisk's Wegovy – is set to lapse in a number of countries in 2026.
The Way Obesity Jabs Function
The injections mimick a biological compound to delay gastric emptying, reduce hunger and boost satiety so individuals consume fewer calories.
People usually begin shedding pounds within a few weeks of starting on the once-weekly jabs.
Research suggests patients may see weight return a year later of halting the treatment, as their typical food cravings return.
Being carrying excess weight elevates your likelihood for contracting health problems, including type 2 diabetes, cardiovascular issues, stroke, and specific cancers.
Obesity concerns individuals in every country and was responsible for over three and a half million fatalities worldwide in 2024, according to the health agency.
